Hospital Resistome Genomics for Infection Ecology Surveillance

Abstract

The rise of antimicrobial resistance (AMR) within healthcare settings poses a formidable threat to patient safety and public health. Hospital resistome genomics a comprehensive approach to characterizing the reservoir of antimicrobial resistance genes (ARGs) in clinical environments has emerged as a transformative tool for infection ecology surveillance. This review synthesizes current evidence on the epidemiology, molecular mechanisms, clinical implications, and surveillance strategies of hospital resistome genomics. It further discusses recent advances, practical integration into infection control, and the outlook for future guideline-based implementation.

Introduction

Antibiotic resistance remains a top global health concern, with hospitals serving as critical hubs for the emergence and transmission of multidrug-resistant organisms (MDROs). Traditional surveillance methods have limitations in identifying resistance mechanisms and tracing transmission dynamics. The implementation of resistome genomics high-throughput sequencing and bioinformatics analysis of ARGs from hospital environments offers unprecedented resolution in mapping the diversity, abundance, and mobility of resistance determinants. This article provides a comprehensive overview of hospital resistome genomics, focusing on its role in infection ecology surveillance and its impact on clinical practice.

Epidemiology / Disease Burden

Nosocomial infections caused by MDROs contribute to significant morbidity, mortality, and healthcare costs worldwide. According to recent global surveillance data, hospital-acquired infections (HAIs) account for millions of cases annually, with AMR implicated in up to 700,000 deaths each year. The burden is particularly acute in intensive care units (ICUs) and surgical wards, where invasive procedures and broad-spectrum antibiotic use create fertile ground for ARG selection and dissemination. Geographic variation in resistome profiles reflects local antimicrobial usage, infection control practices, and patient demographics, underscoring the need for tailored surveillance strategies.

Pathophysiology

The hospital resistome encompasses the totality of ARGs present in microbial communities within the healthcare environment, including patient flora, surfaces, medical equipment, and wastewater. The horizontal gene transfer (HGT) of ARGs mediated by plasmids, transposons, and integrons facilitates rapid adaptation to antimicrobial pressure. Metagenomic sequencing enables detection of both culturable and uncultivable organisms, providing a holistic view of the resistome architecture. Notably, mobile genetic elements (MGEs) act as vectors for the propagation of resistance across diverse bacterial species, fueling outbreaks and undermining therapeutic options.

Risk Factors

Several factors influence the emergence and maintenance of hospital resistomes: excessive or inappropriate antibiotic prescribing, inadequate infection prevention measures, high patient turnover, and the presence of immunocompromised individuals. Environmental reservoirs such as sinks, drains, and biofilms often harbor persistent ARGs, while patient-to-patient transmission can occur via healthcare workers or contaminated equipment. Recent studies underscore the role of environmental cleaning protocols and antimicrobial stewardship programs in mitigating resistome expansion.

Clinical Features

Patients affected by MDROs frequently present with severe, treatment-refractory infections, including bacteremia, pneumonia, urinary tract infections, and surgical site infections. Clinical features may be indistinguishable from those of susceptible pathogens, necessitating laboratory confirmation. The presence of high-risk resistance genes (e.g., blaKPC, mcr-1, vanA) is associated with increased mortality, prolonged hospitalization, and limited therapeutic options, highlighting the critical need for rapid identification and targeted intervention.

Diagnosis

Conventional culture-based diagnostics are often slow and insensitive to the full spectrum of ARGs present in clinical and environmental samples. Next-generation sequencing (NGS) technologies including whole-genome sequencing (WGS) and metagenomic shotgun sequencing enable comprehensive resistome profiling, allowing simultaneous detection of known and novel resistance determinants. Bioinformatics pipelines analyze sequence data to map ARGs, predict phenotypic resistance, and trace transmission networks. Point-of-care molecular assays complement these approaches by offering rapid, actionable results in acute care settings.

Treatment & Management

Management of infections due to MDROs is complex and requires a multifaceted approach. Empirical therapy should be guided by local resistance epidemiology and updated resistome data. De-escalation to targeted therapy is recommended once susceptibility profiles are available. Infection control interventions such as contact precautions, environmental decontamination, and cohorting are essential to prevent further transmission. Antimicrobial stewardship programs play a central role in optimizing antibiotic use and curbing the selective pressure that drives resistome evolution.

Recent Advances / Emerging Therapies

Recent advances in hospital resistome genomics include the integration of real-time sequencing for outbreak investigation, machine learning algorithms for predictive surveillance, and the use of environmental microbiome monitoring to assess intervention efficacy. Novel antimicrobial agents and adjunctive therapies (e.g., bacteriophage therapy, antimicrobial peptides) are being explored to overcome resistant infections. Furthermore, CRISPR-Cas systems offer the potential for targeted ARG disruption, representing a frontier for precision antimicrobial therapy.

Guideline Recommendations

International guidelines from organizations such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and European Centre for Disease Prevention and Control (ECDC) advocate for the incorporation of resistome genomics into routine surveillance and outbreak response. Recommendations emphasize the importance of interdisciplinary collaboration, data sharing, and the development of standardized protocols for sequencing, data analysis, and reporting. Tailored implementation strategies should account for resource availability, infrastructure, and local epidemiological context.

Conclusion

Hospital resistome genomics represents a paradigm shift in infection ecology surveillance, offering granular insights into the origins, dynamics, and transmission of antimicrobial resistance. By bridging microbiology, genomics, and clinical practice, this approach paves the way for precision infection control and more effective stewardship interventions. Continuous innovation, robust guidelines, and investment in infrastructure are essential to realize the full potential of resistome genomics in safeguarding patient outcomes and public health.